Biotech company BioMarin Pharmacuetical's (BMRN) shares are moving sharply higher on heavy volume in Friday's session. This on talk that French pharmaceutical giant, Sanofi (SNY) might be looking to buy the orphan drugmaker. Financial blog Betaville reports that Sanofi has shifted its focus to BioMarin, frustrated after its advances for Medivation have been rejected. But TheStreet's Alicia McElhaney says the talk may be nothing more than just that. Jeanne Yurman reports.
More from Video
CAG has hung onto the bulk of its recent gains, and could rise to the $50 area, according to the charts and indicators.
Breaking down an approach to the long side of this biotech stock.
AMSC CEO discusses that and China challenges.
One of pharma's biggest CEO's talks M&A action on the exchange.